Montag & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Montag & Associates’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.39M	Sell	39,348 -3,080	-7%	-$180K	0.11%	157
2025 Q4	$2.29M	Sell	42,428 -2,870	-6%	-$138K	0.1%	157
2025 Q3	$2.04M	Sell	45,298 -160	-0.4%	-$7.47K	0.09%	168
2025 Q2	$2.1M	Sell	45,458 -71	-0.2%	-$3.48K	0.1%	156
2025 Q1	$2.78M	Sell	45,529 -43,729	-49%	-$2.55M	0.14%	140
2024 Q4	$5.05M	Buy	89,258 +67,966	+319%	+$3.8M	0.24%	88
2024 Q3	$1.1M	Buy	21,292 +893	+4%	+$41.9K	0.05%	240
2024 Q2	$847K	Sell	20,399 -600	-3%	-$26.8K	0.04%	247
2024 Q1	$1.14M	Buy	20,999 +1,758	+9%	+$89.6K	0.06%	228
2023 Q4	$987K	Sell	19,241 -1,555	-7%	-$81.6K	0.06%	228
2023 Q3	$1.21M	Sell	20,796 -475	-2%	-$29.1K	0.08%	199
2023 Q2	$1.36M	Buy	21,271 +46	+0.2%	+$3.08K	0.08%	177
2023 Q1	$1.47M	Hold	21,225	–	–	0.1%	165
2022 Q4	$1.53M	Buy	21,225 +124	+0.6%	+$9.35K	0.1%	165
2022 Q3	$1.5M	Sell	21,101 -143	-0.7%	-$10.4K	0.1%	162
2022 Q2	$1.65M	Sell	21,244 -3,378	-14%	-$257K	0.11%	163
2022 Q1	$1.8M	Sell	24,622 -1,000	-4%	-$67.1K	0.1%	177
2021 Q4	$1.6M	Hold	25,622	–	–	0.08%	193
2021 Q3	$1.52M	Sell	25,622 -160	-0.6%	-$10.5K	0.08%	195
2021 Q2	$1.72M	Hold	25,782	–	–	0.09%	182
2021 Q1	$1.63M	Hold	25,782	–	–	0.09%	186
2020 Q4	$1.6M	Buy	25,782 +1,873	+8%	+$115K	0.1%	169
2020 Q3	$1.44M	Buy	23,909 +1,000	+4%	+$60.2K	0.12%	158
2020 Q2	$1.35M	Sell	22,909 -40	-0.2%	-$2.39K	0.12%	153
2020 Q1	$1.28M	Sell	22,949 -296	-1%	-$18.1K	0.13%	147
2019 Q4	$1.49M	Sell	23,245 -1,421	-6%	-$81.4K	0.12%	153
2019 Q3	$1.25M	Sell	24,666 -895	-4%	-$42.1K	0.11%	161
2019 Q2	$1.16M	Sell	25,561 -3,405	-12%	-$159K	0.1%	167
2019 Q1	$1.38M	Sell	28,966 -7,990	-22%	-$398K	0.13%	146
2018 Q4	$1.92M	Sell	36,956 -9,106	-20%	-$489K	0.21%	111
2018 Q3	$2.86M	Buy	46,062 +31,016	+206%	+$1.84M	0.25%	96
2018 Q2	$833K	Buy	15,046 +290	+2%	+$15.7K	0.09%	171
2018 Q1	$933K	Sell	14,756 -807	-5%	-$51.9K	0.1%	171
2017 Q4	$954K	Buy	15,563 +1,877	+14%	+$117K	0.09%	175
2017 Q3	$872K	Buy	13,686 +104	+0.8%	+$6.07K	0.09%	164
2017 Q2	$757K	Buy	13,582 +200	+1%	+$10.9K	0.08%	158
2017 Q1	$728K	Sell	13,382 -400	-3%	-$21.9K	0.08%	159
2016 Q4	$805K	Buy	13,782 +5	+0%	+$273	0.1%	155
2016 Q3	$743K	Buy	13,777 +494	+4%	+$31.7K	0.09%	157
2016 Q2	$977K	Hold	13,283	–	–	0.13%	144
2016 Q1	$849K	Sell	13,283 -200	-1%	-$12.6K	0.12%	146
2015 Q4	$927K	Sell	13,483 -145	-1%	-$9.58K	0.14%	136
2015 Q3	$807K	Sell	13,628 -1,000	-7%	-$63.4K	0.13%	144
2015 Q2	$973K	Sell	14,628 -500	-3%	-$33K	0.14%	147
2015 Q1	$976K	Buy	15,128 +500	+3%	+$31.3K	0.14%	151
2014 Q4	$863K	Hold	14,628	–	–	0.13%	150
2014 Q3	$749K	Buy	14,628 +4,128	+39%	+$206K	0.12%	151
2014 Q2	$509K	Hold	10,500	–	–	0.08%	178
2014 Q1	$545K	Hold	10,500	–	–	0.09%	164
2013 Q4	$558K	Hold	10,500	–	–	0.1%	156
2013 Q3	$486K	Hold	10,500	–	–	0.09%	156
2013 Q2	$469K	Buy	+10,500	New	+$456K	0.1%	152

Other funds holding BMY

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Montag & Associates's BMY Position: Q1 2026 in Review

Montag & Associates reduced its Bristol-Myers Squibb (BMY) stake by 7.3% in Q1 2026, selling an estimated $180K and leaving 39,348 shares worth $2.39M. The position accounts for 0.11% of the portfolio, ranked #157.

Montag & Associates first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.05M in Q4 2024. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

Montag & Associates held 39,348 shares of Bristol-Myers Squibb worth $2.39M as of Q1 2026.
Montag & Associates sold 3,080 Bristol-Myers Squibb shares in Q1 2026, an estimated $180K.
Bristol-Myers Squibb made up 0.11% of Montag & Associates's portfolio in Q1 2026, its #157 holding.
Montag & Associates first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
Montag & Associates's Bristol-Myers Squibb position peaked at $5.05M in Q4 2024.
2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.